Bellevue Group's 2025 Profit Declines Despite Cost Efficiency Measures

Bellevue Group has announced a net profit of CHF 1.9 million for 2025, influenced by a challenging healthcare sector. The firm's cost base reduction by 16% through efficiency measures was notable. Assets under management stood at CHF 5.3 billion, a 9% reduction year-on-year. The average asset base decreased by 23%, leading to a 25% drop in operating income to CHF 52.6 million.

Despite these challenges, Bellevue's healthcare investment strategies yielded positive returns in USD, with BB Biotech AG outperforming its benchmark by 20%. Operating expenses fell to CHF 49.1 million due to structural efficiency measures. The company proposes a dividend of CHF 0.15 per share.

2026 is seen as a transitional year, with Bellevue focusing on technological investments to secure competitiveness and target growth. The company's strong balance sheet supports these strategic initiatives, positioning it well amidst ongoing market fluctuations.